TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2680157

Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Medical therapy (type 1)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Surgical therapy (type 1)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Medical therapy (type 2)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Surgical therapy (type 2)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Surgical therapy (lowest ejection fraction tercile)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Medical therapy (lowest ejection fraction tercile)
Number of subjects: 468
Study: 132142

Group type: EXPERIMENTAL
Intervention: Topical retinoic acid
Number of subjects: 211

Group type: COMPARATOR
Intervention: Sulfur-resorcinol-salicylic acid
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 31219052

Group type: COMPARATOR
Intervention: Web-based smoking intervention for smokers with no ADS
Number of subjects: 2512

Group type: EXPERIMENTAL
Intervention: Web-based smoking intervention for smokers with depression
Number of subjects: 2512

Group type: EXPERIMENTAL
Intervention: Web-based smoking intervention for smokers with PTSD
Number of subjects: 2512

Group type: EXPERIMENTAL
Intervention: Web-based smoking intervention for smokers with panic disorder
Number of subjects: 2512

Group type: EXPERIMENTAL
Intervention: Web-based smoking intervention for smokers with two or more ADS
Number of subjects: 2512
Study: 28572626

Group type: EXPERIMENTAL
Intervention: Wearing pyjamas
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wearing day clothes
Number of subjects: 30
Study: 26046102

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt containing Bifidobacterium lactis (1×10(6) per gram), 200g once daily for 2 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Normal yogurt, consumed by control group
Number of subjects: 49
Study: 23359066

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 50
Study: 22088897

Group type: EXPERIMENTAL
Intervention: Reading an article about the 2009 USPSTF mammogram guidelines
Number of subjects: 249
Study: 19325490

Group type: EXPERIMENTAL
Intervention: Rivastigmine (3 doses of 1.5 mg per day starting the evening before surgery until the evening of the sixth postoperative day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 120
Study: 16198451

Group type: EXPERIMENTAL
Intervention: Combined pneumococcal conjugate and pneumococcal polysaccharide vaccination
Number of subjects: 0
Study: 15448038

Group type: EXPERIMENTAL
Intervention: 4 mg of zoledronic acid
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 11066186

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 123
Study: 9069483

Group type: EXPERIMENTAL
Intervention: Active warfarin and active aspirin
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Active warfarin and placebo aspirin
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Placebo warfarin and active aspirin
Number of subjects: 405

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 405
Study: 8367963

Group type: EXPERIMENTAL
Intervention: Interpersonal violence incidents
Number of subjects: 640
Study: 3820942

Group type: EXPERIMENTAL
Intervention: Cuprophan membrane with acetate dialysate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Polyacrilonitrile membrane (PAN) with acetate dialysate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: PAN with bicarbonate dialysate
Number of subjects: 13

Group type: COMPARATOR
Intervention: Acetate dialysate (control for PCO2)
Number of subjects: 13
Study: 31972253

Group type: EXPERIMENTAL
Intervention: Real tDCS (n=6)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham tDCS (n=4)
Number of subjects: 24
Study: 29929169

Group type: EXPERIMENTAL
Intervention: IV PCA + posterior QLB with 0.3 ml/kg 0.25% bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: IV PCA + posterior QLB with 0.3 ml/kg 0.9% saline
Number of subjects: 60
Study: 26621483

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC)/azathioprine (AZA)
Number of subjects: 0
Study: 24929235

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Combination of emtricitabine and TDF (FTC/TDF)
Number of subjects: 280
Study: 22415494

Group type: EXPERIMENTAL
Intervention: Iron, folic acid, and cobalamin (Group II)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Iron and folic acid (Group I)
Number of subjects: 150
Study: 20137789

Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: De-alcoholized red wine
Number of subjects: 22
Study: 18930789

Group type: EXPERIMENTAL
Intervention: Radial flow with viewpoint jitter synchronized to lateral head oscillation
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Radial flow with viewpoint jitter viewed by stationary observers
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Radial flow without viewpoint jitter viewed during head oscillation
Number of subjects: 4

Group type: COMPARATOR
Intervention: Radial flow without viewpoint jitter viewed by stationary observers
Number of subjects: 4
Study: 15709999

Group type: EXPERIMENTAL
Intervention: Oligofructose
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study: 11949767

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Haloperidol 3 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: N1/P2 response
Number of subjects: 15
Study: 10505032

Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Age >= 40 years (poor prognostic variable)
Number of subjects: 29
Study: 7753949

Group type: EXPERIMENTAL
Intervention: High-priority instructions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levels-of-processing manipulation
Number of subjects: 0
Study: 2149042

Group type: EXPERIMENTAL
Intervention: Teicoplanin at a dose of 400 mg/d
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Ceftazidime with teicoplanin
Number of subjects: 310

Group type: COMPARATOR
Intervention: Ceftazidime without teicoplanin
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Teicoplanin for Gram-positive Hickman line-associated bacteraemia
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 310
Study: 82086

Group type: EXPERIMENTAL
Intervention: Cimetidine 1.6 g daily for 6 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cimetidine and placebo
Number of subjects: 27
Study: 30112914

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135
Study: 31035212

Group type: EXPERIMENTAL
Intervention: Mobile telephone supported Collaborative Stepped Care (mCSC)
Number of subjects: 895

Group type: COMPARATOR
Intervention: Ordinary Collaborative Stepped Care (oCSC)
Number of subjects: 895
Study: 28150097

Group type: EXPERIMENTAL
Intervention: Direct-mail program to increase CRC screening rates
Number of subjects: 8

Group type: COMPARATOR
Intervention: Implementation challenges faced by community health centers
Number of subjects: 8
Study: 25376433

Group type: EXPERIMENTAL
Intervention: Meta-supervision intervention in addition to usual supervision (n = 40)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Usual supervision (n = 43)
Number of subjects: 83
Study: 23564362

Group type: EXPERIMENTAL
Intervention: Standard intramedullary hip nails
Number of subjects: 33

Group type: COMPARATOR
Intervention: Long intramedullary hip nails
Number of subjects: 33
Study: 21807056

Group type: EXPERIMENTAL
Intervention: DTaP(5)-IPV-Hib
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTaP(3)-IPV/Hib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 19127196

Group type: EXPERIMENTAL
Intervention: Standard padded headgear
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: Modified padded headgear
Number of subjects: 1493

Group type: COMPARATOR
Intervention: Control group (no headgear)
Number of subjects: 1493
Study: 16923922

Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitor
Number of subjects: 10

Group type: COMPARATOR
Intervention: Angiotensin II type 1 receptor antagonist
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination therapy (Angiotensin-converting enzyme inhibitor + Angiotensin II type 1 receptor antagonist)
Number of subjects: 10
Study: 15217999

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg daily from day 3-7 and recombinant FSH (rFSH) 75 IU/day on days 3 and 8
Number of subjects: 38

Group type: COMPARATOR
Intervention: Long GnRH agonist protocol and stimulated with rFSH (300-450 IU/day)
Number of subjects: 38
Study: 11526368

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (AADs) - primarily amiodarone
Number of subjects: 461
Study: 9031954

Group type: EXPERIMENTAL
Intervention: Doppler umbilical artery velocimetry
Number of subjects: 1903
Study: 8497012

Group type: EXPERIMENTAL
Intervention: 1-hour bout of sleep (SB)
Number of subjects: 7

Group type: COMPARATOR
Intervention: No sleep (Control)
Number of subjects: 7
Study: 3306748

Group type: EXPERIMENTAL
Intervention: Caffeine 240 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caffeine 480 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caffeine 720 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 28744796

Group type: EXPERIMENTAL
Intervention: ABT-122 (0.1, 0.3, 1, 3, and 10 mg/kg intravenous; 0.3, 1, and 3 mg/kg subcutaneous)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: ABT-122 (1 mg/kg every other week or 0.5-3 mg/kg every week for 8 weeks)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: ABT-122 (1 mg/kg every other week)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: ABT-122 (0.5-3 mg/kg every week)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: ABT-122 (every week dosing)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: ABT-122
Number of subjects: 79
Study: 27053384

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (3 times daily 117 mg or 350 mg/d)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 25660281

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus L-92
Number of subjects: 49
Study: 22085840

Group type: EXPERIMENTAL
Intervention: Open-wedge high tibial osteotomy
Number of subjects: 28
Study: 20079899

Group type: EXPERIMENTAL
Intervention: metformin (500 mg three times a day) plus simvastatin (20 mg/day)
Number of subjects: 84

Group type: COMPARATOR
Intervention: metformin (500 mg three times a day) plus placebo
Number of subjects: 84
Study: 18462468

Group type: COMPARATOR
Intervention: NTrainer treatment provided to 21 infants.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: NTrainer treatment
Number of subjects: 31
Study: 15998657

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (400 IU/day of vitamin E, 500 mg/day of vitamin C, 6 mg/day of beta-carotene)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 10
Study: 14599049

Group type: EXPERIMENTAL
Intervention: Partially hydrolysed milk formula containing fructo- and galacto-oligosaccharides
Number of subjects: 604
Study: 10561921

Group type: EXPERIMENTAL
Intervention: ChromaGen haploscopic lenses
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo lenses
Number of subjects: 47
Study: 8734674

Group type: EXPERIMENTAL
Intervention: Once-daily aminoglycosides
Number of subjects: 2317
Study: 1885913

Group type: EXPERIMENTAL
Intervention: Sputum induction supervised by nursing and medical staff (group 1)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Sputum induction supervised by an experienced respiratory physiotherapist (group 2)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Bronchoalveolar lavage (BAL)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Induced sputum (adequate samples)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Induced sputum and BAL
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Induced sputum
Number of subjects: 151
Study: 6343340

Group type: EXPERIMENTAL
Intervention: Oral fenoterol 0.8 mg/kg in three divided doses
Number of subjects: 13

Group type: COMPARATOR
Intervention: Inhaled fenoterol (higher than 0.4 mg three times per day)
Number of subjects: 13
Study: 29982562

Group type: EXPERIMENTAL
Intervention: Uninterrupted DOACs
Number of subjects: 846

Group type: COMPARATOR
Intervention: Interrupted DOACs
Number of subjects: 846
Study: 28002165

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) >14 ng/L and NT-proBNP >300 ng/L
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: NT-proBNP cutoff at 108 ng/L
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 572
Study: 25770644

Group type: EXPERIMENTAL
Intervention: KETODEX (low-dose ketamine 0.15 mg/kg followed by dexmedetomidine 0.3 μg/kg i.v.)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control (volume-matched normal saline)
Number of subjects: 92
Study: 24182587

Group type: EXPERIMENTAL
Intervention: RME/FM (Rapid Maxillary Expansion with Facemask)
Number of subjects: 46

Group type: COMPARATOR
Intervention: BAMP (Bone-Anchored Maxillary Protraction)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: RME/FM
Number of subjects: 46

Group type: COMPARATOR
Intervention: BAMP
Number of subjects: 46
Study: 21923002

Group type: EXPERIMENTAL
Intervention: Concept mapping
Number of subjects: 3

Group type: COMPARATOR
Intervention: Traditional care planning
Number of subjects: 3
Study: 18502089

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 6 weeks
Number of subjects: 39
Study: 17122235

Group type: EXPERIMENTAL
Intervention: Lidocaine 2%‐epinephrine (1:200,000)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline‐epinephrine (1:200,000)
Number of subjects: 80
Study: 15556955

Group type: COMPARATOR
Intervention: Exercise classes
Number of subjects: 1334

Group type: COMPARATOR
Intervention: Spinal manipulation
Number of subjects: 1334

Group type: COMPARATOR
Intervention: Manipulation followed by exercise
Number of subjects: 1334
Study: 11575892

Group type: EXPERIMENTAL
Intervention: Easyhaler
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 12

Group type: COMPARATOR
Intervention: pMDI plus Nebuhaler
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nebuhaler
Number of subjects: 12
Study: 9383927

Group type: EXPERIMENTAL
Intervention: Behavioral Family Systems Therapy (BFST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education and Support group (ES)
Number of subjects: 0
Study: 7953032

Group type: EXPERIMENTAL
Intervention: Daily Living Programme (DLP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard in-patient care
Number of subjects: 100
Study: 3435691

Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Combination of diltiazem and propranolol
Number of subjects: 5
Study: 29206720

Group type: EXPERIMENTAL
Intervention: HIV prevention intervention providing 80% reduction in susceptibility per act; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 28770449

Group type: EXPERIMENTAL
Intervention: 30,000 IU oral VitD3/week
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 26791798

Group type: EXPERIMENTAL
Intervention: pemetrexed + cisplatin (500 mg/m² + 75 mg/m²)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: pemetrexed + carboplatin (500 mg/m² + AUC5)
Number of subjects: 122
Study: 23716291

Group type: EXPERIMENTAL
Intervention: MDCT‐CA evaluation by trainee radiologists at baseline, 4 weeks, 8 weeks, and 6 months
Number of subjects: 3
Study: 22024529

Group type: EXPERIMENTAL
Intervention: Opened capsule dosing method (30 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intact capsule dosing method (30 mg)
Number of subjects: 28
Study: 18208955

Group type: EXPERIMENTAL
Intervention: Inferior vena cava (IVC) filters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retrievable IVC filters
Number of subjects: 0
Study: 16390470

Group type: EXPERIMENTAL
Intervention: Intra-oral lubricating device
Number of subjects: 29
Study: 13678775

Group type: EXPERIMENTAL
Intervention: 50 mg i.v. neridronate bimonthly and 500 mg calcium plus 400 U vitamin D supplements daily (n=39)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Calcium-vitamin D supplements alone (control group, n=39)
Number of subjects: 78
Study: 10916115

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg/day (group A)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 57
Study: 8956382

Group type: EXPERIMENTAL
Intervention: Ritanserin 2.5 mg/day or 5 mg/day
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study: 1388038

Group type: EXPERIMENTAL
Intervention: Clodronate 300 mg/day plus hydration
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo plus hydration
Number of subjects: 44
Study: 3894196

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMI)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMI) after placebo
Number of subjects: 17
Study: 31413163

Group type: EXPERIMENTAL
Intervention: Patient-tailored self-management intervention (n=102)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Usual care (UC) (n=99)
Number of subjects: 201
Study: 29167117

Group type: EXPERIMENTAL
Intervention: High-intensity one-legged cycling (HIC; 8 × 4 at 90% one-legged cycling max)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-intensity one-legged cycling (HIC)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (healthy individuals)
Number of subjects: 8
Study: 27482970

Group type: EXPERIMENTAL
Intervention: 1.5 mg esmirtazapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3.0 mg esmirtazapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4.5 mg esmirtazapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25386752

Group type: EXPERIMENTAL
Intervention: Adductor canal block with ropivacaine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 36
Study: 22486948

Group type: EXPERIMENTAL
Intervention: 4000 IU/day vitamin D(3)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 20391060

Group type: EXPERIMENTAL
Intervention: Woman-Focused intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 0
Study: 17908411

Group type: EXPERIMENTAL
Intervention: Unilateral ovarian drilling
Number of subjects: 87

Group type: COMPARATOR
Intervention: Bilateral ovarian drilling
Number of subjects: 87
Study: 16240844

Group type: EXPERIMENTAL
Intervention: Plant-based diet intervention
Number of subjects: 104
Study: 11950006

Group type: EXPERIMENTAL
Intervention: Uncaria tomentosa (UT) extract
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Uncaria tomentosa (UT) extract during second phase
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10023788

Group type: EXPERIMENTAL
Intervention: Salbutamol inhalation
Number of subjects: 0
Study: 7599664

Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) administration of human menopausal gonadotropin (hMG) 150 IU
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) administration of human menopausal gonadotropin (hMG) 150 IU
Number of subjects: 6
Study: 2240506

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 30
Study: 912132

Group type: EXPERIMENTAL
Intervention: Topical nitrogen mustard with and without tolerance induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PUVA in combination with Cyclophosphamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bleomycin and Methotrexate
Number of subjects: 0
Study: 30986736

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy with integrated elements of emotion‐focused therapy (CBT + EFT)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy with treatment components based on self‐regulation theory (CBT + SR)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Patients diagnosed with anxiety disorders
Number of subjects: 47

Group type: COMPARATOR
Intervention: Patients diagnosed with depression
Number of subjects: 47
Study: 28339547

Group type: EXPERIMENTAL
Intervention: Strengthening Families Programme 10-14 (SFP10-14)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 614
Study: 25929897

Group type: EXPERIMENTAL
Intervention: Probiotic preparation (28 capsules over 14 days, twice a day)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Placebo capsules (matching to probiotic preparation)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Probiotic preparation
Number of subjects: 650

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 650
Study: 23587104

Group type: EXPERIMENTAL
Intervention: Self-administered structured questionnaire assessing sexual health knowledge
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Determinants for poor sexual health education in ≤15 years
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Determinants for poor sexual health knowledge in >15 years
Number of subjects: 419